TrialPath
Recruiting

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

NCT07504458 · Quetzal Therapeutics
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia
About this study
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Eligibility criteria
Inclusion Criteria: 1. Informed Consent 2. Participants must be between 18 and under 71 years of age 3. Participants must have a confirmed diagnosis of APL proven by standard genetic testing (t(15;17) or PML-RARA) 4. Participants must be classified as low- or intermediate-risk APL 5. Participants must be willing and able to comply with the scheduled study visits, treatment plans, laboratory tests, contraception guidance, and other procedures Exclusion Criteria 1. Participants who have significant heart rhythm problems including long QT syndrome, serious arrhythmias, very slow heart rate, or prolonged QTc on ECG 2. Participants who have central nervous system leukemia 3. Participants having serious ongoing medical conditions or infections including uncontrolled infections, severe organ disease, or conditions that make study participation unsafe 4. Participants who are pregnant, breastfeeding, or unwilling to use contraception 5. Participants who are unable to safely take study medication, including severe neuropathy, inability to swallow oral medication, malabsorption issues, or known allergy to ATO or ATRA
Study design
Enrollment target: 150 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-06-08
Estimated completion: 2030-12
Last updated: 2026-11-18
Interventions
Drug: QTX-2101 + ATRADrug: IV arsenic trioxide (ATO) + ATRA
Primary outcomes
  • • Maximum observed plasma (concentration (Cmax) of QTX-2101 for ASIII (Up to 1 cycle of consolidation therapy (each cycle is 8 weeks))
  • • Molecular complete remission (molecular CR) rate (Up to 60 days of induction and 3 8-week cycles of consolidation treatment)
Sponsor
Quetzal Therapeutics · industry
All locations (39)
University of Alabama at Birmingham (UAB)Recruiting
Birmingham, Alabama, United States
City of Hope Comprehensive Cancer CenterRecruiting
Duarte, California, United States
University of California, IrvineRecruiting
Irvine, California, United States
USC Norris Comprehensive Cancer CenterRecruiting
Los Angeles, California, United States
UCI Health - UCI Medical CenterRecruiting
Orange, California, United States
Stanford University School of MedicineRecruiting
Stanford, California, United States
Colorado Blood Cancer InstituteRecruiting
Denver, Colorado, United States
Emory Winship Cancer InstituteRecruiting
Atlanta, Georgia, United States
Augusta University Medical CenterRecruiting
Augusta, Georgia, United States
University of Kentucky Markey Cancer CenterRecruiting
Lexington, Kentucky, United States
University of Maryland Medical CenterRecruiting
Baltimore, Maryland, United States
Johns Hopkins Kimmel Cancer CenterRecruiting
Baltimore, Maryland, United States
University of MichiganRecruiting
Ann Arbor, Michigan, United States
Roswell Park Comprehensive Cancer CenterRecruiting
Buffalo, New York, United States
Montefiore Medical CenterRecruiting
The Bronx, New York, United States
University of North Carolina at Chapel HillRecruiting
Chapel Hill, North Carolina, United States
The Ohio State University Wexner Medical CenterRecruiting
Columbus, Ohio, United States
UPMC Hillman Cancer CenterRecruiting
Pittsburgh, Pennsylvania, United States
Sarah Cannon Research Institute at TriStar Centennial Medical CenterRecruiting
Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer CenterRecruiting
Houston, Texas, United States
University of Virginia HealthRecruiting
Charlottesville, Virginia, United States
Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Sud, Centre François MagendieRecruiting
Bordeaux, France
CHU Grenoble Alpes - Hôpital MichallonRecruiting
La Tronche, France
Centre Hospitalier Régional Universitaire (CHRU) de Nancy - Hôpitaux de BraboisRecruiting
Nancy, France
Centre Hospitalier Universitaire (CHU) de Nice - Hôpital de l'Archet 1Recruiting
Nice, France
Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Saint-LouisRecruiting
Paris, France
Centre Hospitalier Universitaire (CHU) de Saint-Étienne - Hôpital NordRecruiting
Saint-Priest-en-Jarez, France
Hôpitaux Universitaires de StrasbourgRecruiting
Strasbourg, France
Hospital Tor Vergata RomaRecruiting
Roma, Italy
Azienda ULSS 8 Berica - Ospedale San BortoloRecruiting
Vicenza, Italy
Institutul Oncologic "Prof. Dr. Ion Chiricuță"Recruiting
Cluj-Napoca, Romania
Hospital Universitari Son EspasesRecruiting
Palma de Mallorca, Balearic Islands, Spain
Institut Català d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i PujolRecruiting
Badalona, Spain
Hospital Universitari Vall d'HebronRecruiting
Barcelona, Spain
Hospital de la Santa Creu i Sant PauRecruiting
Barcelona, Spain
Hospital Universitario San Pedro de AlcántaraRecruiting
Cáceres, Spain
Hospital Regional Universitario de MálagaRecruiting
Málaga, Spain
Hospital Universitario Central de AsturiasRecruiting
Oviedo, Spain
Hospital Universitario y Politécnico La FeRecruiting
Valencia, Spain
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia · TrialPath